COVIMMUNAGE: Factors Influencing the COVID-19 Vaccine Immune Response According to Age and Presence or Not of a Past History of COVID-19
Study Details
Study Description
Brief Summary
Age is the main risk factor associated with the severity of COVID-19. From the beginning of the vaccination campaign, elderly subjects are part of the priority population. However, immunosenescence appears to play a role in the natural post-COVID-19 immunity of convalescent elderly subjects and also in the post-vaccination response. However, vaccination recommendations for both naïve (2 doses of vaccine) and convalescent subjects (1 dose of vaccine) do not differ according to age. To date, there is little data to suggest that the response to the vaccine in naïve or convalescent subjects may vary according to age in terms of qualitative and quantitative response and duration.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 4 |
Detailed Description
In addition, the reactogenicity following the vaccine, remains important with COVID-19 vaccines, whether using an Messenger RiboNucleic Acid (mRNA) technique or an adenovirus vector technique. A better understanding of the parameters of early inflammatory response explaining this reactogenicity would allow to optimize the formulation of future vaccines. There are still several unknowns concerning the post-vaccination immune response (immunogenicity and reactogenicity) in older subjects,depending on their history of COVID-19 and the type of vaccine administered. A better understanding of this immune response is necessary in order to propose the best vaccine strategies and regimens in this high-risk COVID-19 population.
Thus, in partnership with Sanofi Pasteur and Bioaster, the Group On Mucosal Immunity And Pathogens (GIMAP) and Circulating Immune Complexes (CIC) vaccinology team proposes to conduct a study comparing the humoral, cellular, mucosal and reactogenic post-vaccination immune response in subjects with a history of COVID-19 >3 months ago (convalescent, 1 dose of vaccine) versus subjects with no history of COVID-19 (naive, 1 or 2 doses of vaccine depending on the type of vaccine used) according to age.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: convalescent participants PFIZER Participants with prior history of COVID-19 in ≥3 months, virologically confirmed and vaccinated by anti-covid19 Pfizer vaccine |
Biological: COVID-19 vaccine Pfizer (1 dose)
A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
|
Experimental: Naive participants PFIZER Participant without past history of COVID-19 and vaccinated by anti-covid19 Pfizer vaccine |
Biological: COVID-19 vaccine Pfizer (2 doses)
A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
|
Experimental: convalescent participants MODERNA Participants with prior history of COVID-19 in ≥3 months, virologically confirmed and vaccinated by anti-covid19 Moderna vaccine |
Biological: COVID-19 mRNA Vaccine Moderna (1 dose)
A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
|
Experimental: Naive participants MODERNA Participant without past history of COVID-19 and vaccinated by anti-covid19 Moderna vaccine |
Biological: COVID-19 mRNA Vaccine Moderna (2 doses)
A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
|
Outcome Measures
Primary Outcome Measures
- Anti-S neutralizing antibody titer [At 15 days after the last dose of vaccine]
The neutralizing antibody titer against protein S from the majority variants at the time of sampling and vaccine S will be evaluated in viral neutralization and pseudoneutralization
Secondary Outcome Measures
- Kinetic of Anti-S antibody titer [At 15 days, 3, 6 and 12 months after the last dose of vaccine]
The antibody titer against protein S will be evaluated by ELISA
- Kinetic of Anti-N antibody titer [At 15 days, 3, 6 and 12 months after the last dose of vaccine]
The antibody titer against protein N will be evaluated by ELISA
- Kinetic of Anti-SARS-CoV-2 immunoglobulin A (IgA) titers in saliva [At 15 days, 3, 6 and 12 months after the last dose of vaccine]
- Kinetic of SARS-CoV-2 quantiferon value [At 15 days, 3, 6 and 12 months after the last dose of vaccine]
- CD4 and CD8 lymphocyte polarization specific to the vaccine S protein [At 15 days after the last dose of vaccine]
Evaluate by TruCulture (Myriad) methode
- Anti-S neutralizing antibody titer [At 3, 6 and 12 months after the last dose of vaccine]
The neutralizing antibody titer against protein S from the majority variants at the time of sampling and vaccine S will be evaluated in viral neutralization and pseudoneutralization
- Kinetic of serum cytokine levels [At 24 and 72 hours after each dose of vaccine]
- Kinetic of C-reactive protein [At 24 and 72 hours after each dose of vaccine]
- Kinetic of vaccine-induced genes signatures [At 24 and 72 hours after each dose of vaccine]
Expression kinetics in foldchange (transcriptomics) of vaccine-induced gene signatures in peripheral blood mononuclear cells
Eligibility Criteria
Criteria
Inclusion Criteria:
-
For the group with a past history of COVID-19 (convalescents)= subject within ≥ 3 months after infection
-
For the NO past history of COVID-19 (naives), subject with no known history of COVID-19
-
Patient affiliated or entitled to a social security plan
-
Patients who have received informed information about the study and who have co-signed a consent to participate in the study with the investigator
Exclusion Criteria:
-
Immunocompromised or under immunosuppressive treatment
-
Subject with a history of COVID hospitalized in intensive care
-
Subject allergic to one of the components of the vaccines used in the study
-
subject vaccinated for COVID-19
-
Subject with persistent symptoms of COVID-19 (long COVID)
-
Subjects with unstable chronic pathology
-
Persons deprived of liberty, hospitalized without consent
-
Pregnant or breastfeeding woman
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | HCL - Hôpital Croix Rousse | Lyon | France | 69004 | |
2 | HCL - Hôpital Edouard Herriot | Lyon | France | 69008 | |
3 | CHU de Saint-Etienne | Saint-Étienne | France | 42055 |
Sponsors and Collaborators
- Centre Hospitalier Universitaire de Saint Etienne
- Sanofi Pasteur, a Sanofi Company
- Bioaster
Investigators
- Principal Investigator: Elisabeth BOTELHO-NEVERS, MD PhD, CHU de St Etienne
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 21CH134
- 2021-003547-24